Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. BioInvent International AB's current 3-Year Share Buyback Ratio was -0.40%.
The historical rank and industry rank for BioInvent International AB's 3-Year Share Buyback Ratio or its related term are showing as below:
BOVNF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -59.8 Med: -17.5 Max: -0.4
Current: -0.4
During the past 13 years, BioInvent International AB's highest 3-Year Share Buyback Ratio was -0.40%. The lowest was -59.80%. And the median was -17.50%.
BOVNF's 3-Year Share Buyback Ratio is ranked better than 86.55% of 1190
companies
in the Biotechnology industry
Industry Median: -11.75
vs BOVNF: -0.40
BioInvent International AB (OTCPK:BOVNF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
BioInvent International AB 3-Year Share Buyback Ratio Related Terms
BOVNF vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, BioInvent International AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's 3-Year Share Buyback Ratio falls into.
BioInvent International AB 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -0.40 mean?
BioInvent International AB (BOVNF) has a 3-Year Share Buyback Ratio of -0.40 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #160 out of 1190 companies in the Biotechnology industry, placing it in the top 13.4%.
Is BioInvent International AB's 3-Year Share Buyback Ratio too high?
BioInvent International AB's current 3-Year Share Buyback Ratio is -0.40. Based on the distribution chart, BioInvent International AB ranks #160 out of 1190 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioInvent International AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #160 out of 1190 companies for 3-Year Share Buyback Ratio. This places BioInvent International AB in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for BioInvent International AB and its competitors. BioInvent International AB's current 3-Year Share Buyback Ratio is -0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current 3-Year Share Buyback Ratio of -0.40. The stock's GF Value™ is $6.44, compared to a current price of $3.29 — trading 48.9% below its estimated fair value. The current 3-Year Share Buyback Ratio is -0.40. BioInvent International AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current 3-Year Share Buyback Ratio is -0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 48.9% below its estimated GF Value™ of $6.44.
Key valuation signals for BOVNF:
3-Year Share Buyback Ratio: -0.40
GF Value™: $6.44 vs. price of $3.29 (48.9% below fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
44GF Score
Get the complete analysis for BOVNF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
